Rhythm Pharmaceuticals Regains Licensing Rights to Imcivree Obesity Drug

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

Rhythm Pharmaceuticals Regains Licensing Rights to Imcivree Obesity Drug

, MT Newswires - 5:29 PM ET 3/20/2025 default

05:29 PM EDT, 03/20/2025 (MT Newswires) -- Rhythm Pharmaceuticals ( RYTM ) said late Thursday it has reacquired rights to its Imcivree obesity medication throughout mainland China, Hong Kong and Macau after terminating its 2021 licensing deal with RareStone Group.

As part of the agreement to regain the global franchise for Imcivree, Rhythm said it will repay $6.3 million in cash to RareStone and return all RareStone shares acquired under the original deal with no additional consideration.

Rhythm is also expecting to report topline data from clinical testing of Imcivree now underway in North America, Europe and Japan in patients with acquired hypothalamic obesity during Q2, it added.

Shares of the company were up 1.4% in recent after-hours activity.

Price: 55.00, Change: +0.77, Percent Change: +1.42

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.